UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
Werte in diesem Artikel
UnitedHealth Group Incorporated UNH continues to face challenges amid a turbulent healthcare insurance landscape. The passage of the “One Big Beautiful Bill Act” through Congress, ready for President Donald Trump’s signature, threatens to significantly reduce federal Medicaid spending. According to reports, approximately 11.8 million Americans are expected to lose Medicaid coverage by 2034, with 5.2 million affected by new work requirements alone.To curb state-level Medicaid expenditures, the bill gradually limits the use of “provider taxes” as a revenue source. However, it also allocates $50 billion in funding to support rural hospitals impacted by these cuts. While insurers like UnitedHealth and Humana Inc. HUM may encounter short-term pressure from shrinking Medicaid rolls, they could ultimately benefit as displaced members shift toward private coverage options.UnitedHealth’s Medicaid membership declined 4% in 2023, 5.2% in 2024, and 1.4% in the first quarter of 2025. The proposed elimination of ACA marketplace tax credits will likely propel more people into employer-sponsored plans. Meanwhile, Medicare Advantage may gain traction, as seniors grapple with increased out-of-pocket expenses due to rollbacks in Medicare Savings Programs. UnitedHealth’s Medicare Advantage enrollment rose by 8.3% in 2023, 1.9% in 2024, and 6.3% in the first quarter of 2025.Another major development shook the market as Centene Corporation CNC, a major Medicaid player, withdrew its 2025 earnings guidance late Tuesday, citing unexpected enrollment shifts and higher medical costs. The move, mirroring UnitedHealth’s earlier decision, rattled the managed care sector. Centene shares witnessed massive declines following the news, and peers like UnitedHealth and Humana followed suit.Centene shares plummeted 41.2% following the announcement, dragging down peers: UnitedHealth and Humana dropped 5.4% and 5.1%, respectively, despite broader market gains driven by tech strength and encouraging jobs data.Price Performance Comparison – UNH, HUM & CNC Image Source: Zacks Investment ResearchUnitedHealth’s Valuation and EstimatesFrom a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 12.99, up from the industry average of 11.49. UNH currently carries a Value Score of A. Image Source: Zacks Investment ResearchThe Zacks Consensus Estimate for UnitedHealth’s 2025 earnings is pegged at $22.07 per share, implying a 20.2% drop from the year-ago period. Image Source: Zacks Investment ResearchThe stock currently carries a Zacks Rank #5 (Strong Sell).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Humana Inc. (HUM): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Centene und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Centene
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Centene
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu UnitedHealth Inc.
Analysen zu UnitedHealth Inc.
Datum | Rating | Analyst | |
---|---|---|---|
14.04.2022 | UnitedHealth Outperform | RBC Capital Markets | |
15.10.2020 | UnitedHealth Outperform | Credit Suisse Group | |
14.10.2020 | UnitedHealth Outperform | RBC Capital Markets | |
29.08.2019 | UnitedHealth Outperform | Credit Suisse Group | |
17.07.2018 | UnitedHealth buy | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
14.04.2022 | UnitedHealth Outperform | RBC Capital Markets | |
15.10.2020 | UnitedHealth Outperform | Credit Suisse Group | |
14.10.2020 | UnitedHealth Outperform | RBC Capital Markets | |
29.08.2019 | UnitedHealth Outperform | Credit Suisse Group | |
17.07.2018 | UnitedHealth buy | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
09.11.2016 | UnitedHealth Group Neutral | Mizuho | |
31.03.2011 | UnitedHealth Group perform | Oppenheimer & Co. Inc. | |
08.02.2011 | UnitedHealth Group neutral | Goldman Sachs Group Inc. | |
15.11.2010 | UnitedHealth Group hold | Stifel, Nicolaus & Co., Inc. | |
20.04.2010 | UnitedHealth neutral | Wedbush Morgan Securities Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
11.06.2009 | UnitedHealth underperform | Oppenheimer & Co. Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für UnitedHealth Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen